top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.
globenewswire.com/ne...-for-Ganaxolone.html
globenewswire.com/ne...-for-Ganaxolone.html